• Policy
• Ildong to continue oral 'GLP-1 receptor agonist' trial
• by Lee, Hye-Kyung Aug 22, 2024 05:55am

• Policy
• Preferential pricing delayed for homegrown new drugs
• by Lee, Tak-Sun Aug 22, 2024 05:50am

• Policy
• Takeda receives P3T approval for TAK-861 in Korea
• by Lee, Hye-Kyung Aug 21, 2024 05:48am

• Policy
• Orphan drug 'Jaypirca' for Mantle Cell Lymphoma wins nod
• by Lee, Hye-Kyung Aug 21, 2024 05:47am

• Policy
• Reevaluation of foreign drug price comparisons
• by Lee, Tak-Sun Aug 21, 2024 05:47am

• Policy
• MFDS reviews COVID-19 drugs Xocova and Lagevrio
• by Lee, Hye-Kyung Aug 21, 2024 05:47am

• Policy
• New criteria set for flexible ICER threshold evaluations
• by Lee, Tak-Sun Aug 20, 2024 06:34am

• Policy
• KDCA apologizes for COVID-19 drug shortages
• by Lee, Hye-Kyung Aug 19, 2024 05:47am

• Policy
• Will Paxlovid soon be reimbursed in Korea?
• by Lee, Tak-Sun Aug 19, 2024 05:47am

• Policy
• KDCA operates Public-Private Council for COVID-19 response
• by Kang, Hye-Kyung Aug 16, 2024 05:56am